Neonatal sepsis is one of the major causes of morbidity and mortality in newborns. In developing countries, multiple drug resistant (MDR) organisms causing neonatal sepsis are threat to current b lactam therapy leading to treatment failure. Emergence of ESBLs and MBLs are a vital factor in the treatment of infections associated with sepsis. This study aims at phenotypic detection of Extended spectrum β-lactamases (ESBL) and Metallo β-lactamases (MBL) producing Enterobacteriaceae isolates of Neonatal Sepsis and to assess the burden of MDR. Total 19 clinical isolates of Enterobacteriaceae were isolated from 115blood samples of suspected cases. Antimicrobial susceptibility was determined by Kirby–Bauer's disk diffusion method. Isolates were screened for ESBL and MBL production by Clinical and Laboratory Standards Institute (CLSI) disk method, and confirmation was done by CLSI phenotypic disk confirmatory test. Out of 115 cases, 19 (17%) were culture positive. Among them, 13(68.4%) were Klebsiella pneumoniae, 4(21%) were Escherichia coli and 2(10.5%) were Citrobacter species. Most of the isolates of Escherichia coli and Klebsiella pneumoniae were resistant to more than two drugs. Citrobacter spp. were resistant to all the drugs except Amikacin. Among 19 isolates, 3(15.7%) of Escherichia coli isolates were ESBL producers and 2(15.3%) of Klebsiella pneumoniae isolates were MBL producers. Continued monitoring of antibiotic susceptibility pattern and routine detection of ESBL and MBL is required in hospitals and private laboratories. The resistance pattern and early detection of ESBL and MBL producing isolates would be important for reducing neonatal morbidity and mortality rates.